Back to News
Market Impact: 0.35
Regeneron: Why I Still See Upside After The Rally
Source: seekingalpha.com
Company FundamentalsCorporate EarningsRegulation & LegislationAnalyst Insights
Regeneron’s Dupixent delivered €5.15B in Q2 sales, up 23.6% sequentially, offsetting ongoing U.S. Eylea pressure from biosimilar launches. The article notes the Eylea decline is no longer weighing on REGN shares, implying improved near-term revenue momentum driven by Dupixent growth.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
REGN0.55
More News
- Delta Air Lines cuts 2026 forecast on fuel surge, but CEO says demand is still strong
- Why is T-Mobile stock tumbling today?
- This exchange stock is a buy on renewed options deal, Morgan Stanley says
- India calls JD Vance's comments about immigrants 'deeply offensive'
- The AI race may be decided by financing—not just better chips
- Why is Verizon stock sliding today?